To further extend our findings and examine the ability of IGFBP‐4 to reduce ongoing severe fibrosis, we tested the effects of expressing human IGFBP‐4 in lung tissues derived from patients with SSc undergoing lung transplantation. The gene discussed is IGFBP4; the disease is systemic sclerosis.